BR112015029038A2 - comprimido engolível, e, processo para preparação de um comprimido engolível - Google Patents

comprimido engolível, e, processo para preparação de um comprimido engolível

Info

Publication number
BR112015029038A2
BR112015029038A2 BR112015029038A BR112015029038A BR112015029038A2 BR 112015029038 A2 BR112015029038 A2 BR 112015029038A2 BR 112015029038 A BR112015029038 A BR 112015029038A BR 112015029038 A BR112015029038 A BR 112015029038A BR 112015029038 A2 BR112015029038 A2 BR 112015029038A2
Authority
BR
Brazil
Prior art keywords
swallowable
preparing
swallowable tablet
tablets
tablet
Prior art date
Application number
BR112015029038A
Other languages
English (en)
Other versions
BR112015029038B1 (pt
Inventor
Moretto Alberto
De Lazzari Alessandra
Original Assignee
Zambon Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48748383&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112015029038(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zambon Spa filed Critical Zambon Spa
Publication of BR112015029038A2 publication Critical patent/BR112015029038A2/pt
Publication of BR112015029038B1 publication Critical patent/BR112015029038B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

1 / 1 resumo “comprimido engolãvel, e, processo para preparaã‡ãƒo de um comprimido engolãvel” esta invenã§ã£o refere-se aos comprimidos engolã­veis contendo pelo menos 80% em peso de n-acetilcisteã­na (nac) e pelo menos um excipiente farmaceuticamente aceitã¡vel, em particular comprimidos nos quais o odor de enxofre estã¡ ausente, em que os ditos comprimidos sã£o montados usando um granulado preparado por meio de um processo de granulaã§ã£o seca do ingrediente ativo sozinho, com o qual os excipientes sã£o misturados antes da compressã£o.
BR112015029038-8A 2013-05-29 2014-05-27 Comprimido engolível, e, processo para preparação de um comprimido engolível BR112015029038B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT000874A ITMI20130874A1 (it) 2013-05-29 2013-05-29 Compresse deglutibili di n-acetilcisteina
ITMI2013A000874 2013-05-29
PCT/EP2014/060950 WO2014191410A1 (en) 2013-05-29 2014-05-27 Swallowable n-acetylcysteine tablets

Publications (2)

Publication Number Publication Date
BR112015029038A2 true BR112015029038A2 (pt) 2017-07-25
BR112015029038B1 BR112015029038B1 (pt) 2022-12-06

Family

ID=48748383

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015029038-8A BR112015029038B1 (pt) 2013-05-29 2014-05-27 Comprimido engolível, e, processo para preparação de um comprimido engolível

Country Status (29)

Country Link
US (1) US9808427B2 (pt)
EP (1) EP3003278B1 (pt)
JP (1) JP6438013B2 (pt)
CN (1) CN105228595B (pt)
AU (1) AU2014273148B2 (pt)
BR (1) BR112015029038B1 (pt)
CA (1) CA2911474C (pt)
CY (1) CY1122114T1 (pt)
DK (1) DK3003278T3 (pt)
EA (1) EA031856B1 (pt)
ES (1) ES2721649T3 (pt)
HR (1) HRP20190687T1 (pt)
HU (1) HUE044880T2 (pt)
IL (1) IL242439B (pt)
IT (1) ITMI20130874A1 (pt)
LT (1) LT3003278T (pt)
MX (1) MX366917B (pt)
MY (1) MY174005A (pt)
PE (1) PE20160184A1 (pt)
PH (1) PH12015502608B1 (pt)
PL (1) PL3003278T3 (pt)
PT (1) PT3003278T (pt)
RS (1) RS58653B1 (pt)
SG (2) SG10201709861YA (pt)
SI (1) SI3003278T1 (pt)
TR (1) TR201906101T4 (pt)
UA (1) UA117829C2 (pt)
WO (1) WO2014191410A1 (pt)
ZA (1) ZA201508411B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3554491T3 (en) * 2016-12-15 2023-05-15 Zambon Spa N-acetylcystein til anvendelse som antibakterielt middel
IT201700109080A1 (it) * 2017-09-28 2019-03-28 Neilos S R L Composizione per la prevenzione e/o il trattamento delle affezioni delle vie respiratorie
BR112020008653A2 (pt) * 2017-11-02 2020-10-27 Zambon S.P.A. composições farmacêuticas compreendendo safinamida
US10288629B1 (en) * 2017-12-19 2019-05-14 Aeterna Zentaris, Inc. Method of assessing growth hormone deficiency in humans by a macimorelin containing composition
EP3806828A1 (en) * 2018-06-14 2021-04-21 Poxel Film-coated tablet comprising a triazine derivative for use in the treatment of diabetes
IT201800007928A1 (it) * 2018-08-07 2020-02-07 Sofar Spa Composizione contenente un agente mucolitico per il trattamento di ipersecrezione di muco e dispositivo per il suo dosaggio
CN112843008A (zh) * 2021-02-07 2021-05-28 广东赛康制药厂有限公司 一种乙酰半胱氨酸片及其制备方法
CN114886860B (zh) * 2022-06-28 2023-04-25 山东达因海洋生物制药股份有限公司 一种乙酰半胱氨酸药物组合物及其制剂和制备工艺

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0481294B2 (de) * 1990-10-19 2001-04-11 Spirig Ag Pharmazeutische Präparate Feste, schnell-lösliche Arzneimittelzubereitung enthaltend N-Acetylcystein
GB9305058D0 (en) * 1993-03-12 1993-04-28 Penn Pharm Ltd Pharmaceutical compositions
IT1311907B1 (it) * 1999-04-06 2002-03-20 Zambon Spa Compresse deglutibili ad alto contenuto di n-acetilcisteina.
US6623754B2 (en) * 2001-05-21 2003-09-23 Noveon Ip Holdings Corp. Dosage form of N-acetyl cysteine
JP2003155232A (ja) * 2001-09-07 2003-05-27 Takeda Chem Ind Ltd 不快な臭いが低減されたｌ−システイン配合固形製剤およびその製造方法
US20080139654A1 (en) * 2006-12-09 2008-06-12 Eric Mott Soderling Acetaminophen compositions having minimized side effects including reduced hepatotoxicity
IT1399492B1 (it) * 2010-04-13 2013-04-19 Alpex Pharma Sa Composizioni farmaceutiche effervescenti contenenti n-acetilcisteina.
EP2574333B1 (en) * 2011-09-27 2017-01-11 Friulchem SpA N-acetylcysteine effervescent tablet and its therapeutical applications

Also Published As

Publication number Publication date
SG11201509177VA (en) 2015-12-30
HRP20190687T1 (hr) 2019-06-14
UA117829C2 (uk) 2018-10-10
ZA201508411B (en) 2022-03-30
BR112015029038B1 (pt) 2022-12-06
LT3003278T (lt) 2019-05-10
MY174005A (en) 2020-03-03
US9808427B2 (en) 2017-11-07
AU2014273148A1 (en) 2015-11-26
IL242439B (en) 2020-01-30
WO2014191410A1 (en) 2014-12-04
SG10201709861YA (en) 2018-01-30
PL3003278T3 (pl) 2019-07-31
EA201592172A1 (ru) 2016-05-31
JP2016520108A (ja) 2016-07-11
MX366917B (es) 2019-07-30
CY1122114T1 (el) 2020-07-31
TR201906101T4 (tr) 2019-05-21
HUE044880T2 (hu) 2019-11-28
ITMI20130874A1 (it) 2014-11-30
CN105228595B (zh) 2019-01-04
DK3003278T3 (da) 2019-05-06
EP3003278A1 (en) 2016-04-13
CA2911474A1 (en) 2014-12-04
PH12015502608A1 (en) 2016-02-29
US20160113876A1 (en) 2016-04-28
PT3003278T (pt) 2019-05-14
EA031856B1 (ru) 2019-03-29
RS58653B1 (sr) 2019-05-31
EP3003278B1 (en) 2019-02-27
AU2014273148B2 (en) 2019-02-28
CA2911474C (en) 2021-04-13
CN105228595A (zh) 2016-01-06
MX2015016130A (es) 2016-08-08
PH12015502608B1 (en) 2016-02-29
SI3003278T1 (sl) 2019-08-30
JP6438013B2 (ja) 2018-12-12
PE20160184A1 (es) 2016-04-27
ES2721649T3 (es) 2019-08-02

Similar Documents

Publication Publication Date Title
BR112015029038A2 (pt) comprimido engolível, e, processo para preparação de um comprimido engolível
CL2012001722A1 (es) Compuestos derivados de 3-hidroxi-5-arilisotiazol, agonistas del receptor 40 acoplado a la proteina g (gpr40); composición farmacéutica que los comprende; y método para el tratamiento o la prevención de la diabetes.
CL2015002164A1 (es) Formulación combinada de dos compuesos antivirales.
EA201591003A1 (ru) Производные бороновой кислоты и их терапевтическое применение
GT201400111A (es) Triazolopiridinas sustituidas
UY33241A (es) ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?.
UY30573A1 (es) N-(1-hetaril-piperidin-4-il)-(het)arilamidas como moduladores del receptor ep2
BR112017007123A2 (pt) derivados de tetrahidroisoquinolina
CL2013003372A1 (es) Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes.
CL2013001295A1 (es) Compuestos derivados de 2,3-dihidromidazo (1,2-c) quinazolina sustituidos con aminoalcoholes; compuesto intermediario y su uso; composicion farmaceutica; combinacion farmaceutica; y su uso para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogenesis.
CL2008002076A1 (es) Compuestos derivados de ariloxazoles sustituidos; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso para tratar diabetes, sindrome metabolico, dislipidemias, entre otras enfermedades.
EA201691216A1 (ru) Композиции линаклотида с замедленным высвобождением
EA201691322A1 (ru) Фармацевтическая композиция ингибитора dpp-iv в комбинации с метформином
ECSP11011076A (es) Tratamiento de trastornos cognitivos con (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma
CL2016002510A1 (es) 2-amino-6-metil-4,4a,5,6-tetrahidropirano [3,4-d][1,3] tiazin-8a(8h)-il-1,3-tiazol-4-ilamidas.
SV2018005760A (es) Derivados de aminotiazol utiles como agentes antiviricos
EA201591618A1 (ru) Замещенные имидазопиридазины
CR20160460A (es) Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados
GT201500035A (es) Composición farmacéutica oral en forma de microesferas y proceso de elaboración
EA201200616A1 (ru) Производные 2-оксо-1-пирролидинилимидазотиадиазола
BR112015021534A2 (pt) composto, e, composições farmacêuticas
BR112013008749A2 (pt) análogos de ciclosporina
EA201500245A1 (ru) Твердый фармацевтический препарат, который содержит левотироксин
CL2008000463A1 (es) Compuestos derivados de benzofuranos sustituidos; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar infecciones parasitarias.
BR112014032583A2 (pt) forma farmacêutica para liberação prolongada de substâncias ativas

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/05/2014, OBSERVADAS AS CONDICOES LEGAIS